- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
FDC's Q3 FY26 saw revenue at Rs. 465 Cr (+0.1%) & PAT at Rs. 28 Cr (-23.6%). Domestic sales dragged, but Export Formulations soared +55%. US business is recovering, boosted by a key US FDA approval for Pilocarpine Ophthalmic Solution.